Sessions

Industry 4.0 Approaches Transforming Cell and Gene Therapy
Changing the Cell Therapy Landscape with In-Vivo Therapies: Is this a Viable Alternative for Point of Care Therapeutics?
Achieving Best Practice in Quality Control and Assurance
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Analytics, Data and IT Tech Solutions: An Overview of Best Practices and Technology
Delivery Solutions, Improvements and Alternatives for Gene & Cell Therapy
Accelerating the Digitalisation Revolution in Cell and Gene Therapy Development
Viral Vector Development: Safe and Effective Viral Vectors for Therapeutic Success

Industry 4.0 Approaches Transforming Cell and Gene Therapy

27 Jan 2022
11:00
SPONSORED BY
WuXi Advanced Therapies
Sexton Biotechnologies
Autolomous

11:00 Chairperson’s Opening
Dragan Djordjevic, Associate Director, Cell Therapy Robotics, Data Automation and Machine Learning, Takeda

11:05 Building Better, Faster, Cheaper Enhanced Immunity

  • New designs and enhancers
  • Advanced x 4 manufacturing
  • Advancing access to advanced therapies

Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania; President, International Society for Cell & Gene Therapy

11:20 TESSA Technology: A New Era for AAV Manufacture

  • Scalable, plasmid free platform for AAV manufacturing
  • TESSA adenoviral systems significantly improve AAV yields
  • TESSA-derived AAV is more infectious, more potent, and better packaged than AAV made using plasmids
  • Scaling up TESSA-based vectors for GMP manufacturing

Ryan Cawood, Chief Scientific Officer, WuXi Advanced Therapeutics and OXGENE

11:35 What Does Industry 4.0 Mean for Single Use Disposables 

  • What are the prior revolutions for single use disposables?
  • What does compatibility and automation looks like as we evolve into the future?
  • Sexton example of forward thinking

Sean Werner, President, Sexton Biotechnologies

11:50 Industry 4.0 Approaches to Data Integration for CGT Manufacturing

Did you know that the majority of CGT manufacturing rely on pen and paper? Autolomous’ platform aims to unlock the power of data to address many of the challenges within CGT manufacturing scale out and up in a safe and compliant manner

  • Data risks and challenges with current manufacturing strategies
  • Opportunities to do more with less
  • AutoloMATE

Kwok Pang, Chief Operating Officer and Co-Founder, Autolomous

12:05 Speaker Q&A and Panel Discussion

Speakers

Dragan Djordjevic
Associate Director, Cell Therapy Robotics, Data Automation and Machine Learning
Takeda
Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy; President, International Society for Cell & Gene Therapy
University of Pennsylvania
Ryan Cawood
Chief Scientific Officer
WuXi Advanced Therapies
Sean Werner
President
Sexton Biotechnologies
Kwok Pang
Chief Operating Officer and Co-Founder
Autolomous